Aggregate development and regulatory milestones eligible to receive.

No definition available.

Name:	antx_AggregateDevelopmentAndRegulatoryMilestonesEligibleToReceive
Namespace Prefix:	antx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Aggregate maximum payments upon achievement of commercial and sales threshold milestones.

+ References

No definition available.

+ Details

Name:	antx_AggregateMaximumPaymentsUponAchievementOfCommercialAndSalesThresholdMilestones
Namespace Prefix:	antx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Aggregate maximum payments upon achievement of development milestones.

+ References

No definition available.

+ Details

Name:	antx_AggregateMaximumPaymentsUponAchievementOfDevelopmentMilestones
Namespace Prefix:	antx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Collaboration, license and other agreements.

+ References

No definition available.

+ Details

Name:	antx_CollaborationLicenseAndOtherAgreementsLineItems
Namespace Prefix:	antx_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of days convenience upon written notice thereafter.

+ References

No definition available.

+ Details

Name:	antx_NumberOfDaysConvenienceUponWrittenNoticeThereafter
Namespace Prefix:	antx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of days convenience upon written notice until first regulatory approval.

+ References

No definition available.

+ Details

Name:	antx_NumberOfDaysConvenienceUponWrittenNoticeUntilFirstRegulatoryApproval
Namespace Prefix:	antx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of years sales royalty required to be paid.

+ References

No definition available.

+ Details

Name:	antx_NumberOfYearsSalesRoyaltyRequiredToBePaid
Namespace Prefix:	antx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Payment of non-refundable upfront payment.

+ References

No definition available.

+ Details

Name:	antx_PaymentOfNonRefundableUpfrontPayment
Namespace Prefix:	antx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Royalty percentage.

+ References

No definition available.

+ Details

Name:	antx_RoyaltyPercentage
Namespace Prefix:	antx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Upfront payment received.

+ References

No definition available.

+ Details

Name:	antx_UpfrontPaymentReceived
Namespace Prefix:	antx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-18

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=antx_AnacorLicensingAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=antx_BriiBiosciencesAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration, License and Other Agreements - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended
	Nov. 30, 2019	Mar. 31, 2026	Mar. 31, 2025
Collaboration, License And Other Agreements [Line Items]
Research and development		$ 6,743,000	$ 7,690,000
Anacor Licensing Agreement
Collaboration, License And Other Agreements [Line Items]
Number of days convenience upon written notice until first regulatory approval.	90 days
Number of days convenience upon written notice thereafter	1 year
Payment of non-refundable upfront payment	$ 2,000,000
Research and development		$ 0	$ 0
Aggregate maximum payments upon achievement of development milestones	2,000,000
Aggregate maximum payments upon achievement of commercial and sales threshold milestones	$ 125,000,000
Royalty percentage	50.00%
Number of years, sales royalty required to be paid	15 years
Brii Biosciences Agreement
Collaboration, License And Other Agreements [Line Items]
Aggregate maximum payments upon achievement of commercial and sales threshold milestones	$ 150,000,000
Number of years, sales royalty required to be paid	15 years
Upfront payment received	$ 0
Brii Biosciences Agreement \| Maximum
Collaboration, License And Other Agreements [Line Items]
Aggregate development and regulatory milestones eligible to receive	$ 15,000,000